International Pediatric MS Study Group Clinical Trials Summit Meeting report

被引:43
|
作者
Chitnis, Tanuja [1 ]
Tardieu, Marc [2 ]
Amato, Maria Pia [3 ]
Banwell, Brenda [4 ]
Bar-Or, Amit [5 ]
Ghezzi, Angelo [6 ]
Kornberg, Andrew [7 ]
Krupp, Lauren B. [8 ]
Pohl, Daniela [9 ]
Rostasy, Kevin [10 ]
Tenembaum, Silvia [11 ]
Waubant, Emmanuelle [12 ]
Wassmer, Evangeline [13 ]
机构
[1] Massachusetts Gen Hosp, Partners Pediat Multiple Sclerosis Ctr, Boston, MA 02114 USA
[2] Hop Univ Paris Sud, Assistance Publ Hop Paris, Paris, France
[3] Univ Florence, Dept Neurol, Florence, Italy
[4] Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada
[5] McGill Univ, Montreal Neurol Inst & Hosp, Montreal, PQ, Canada
[6] Hosp Gallarate, Multiple Sclerosis Study Ctr, Gallarate, Italy
[7] Royal Childrens Hosp, Parkville, Vic 3052, Australia
[8] Lourie Ctr Pediat MS, Stony Brook, NY USA
[9] Univ Ottawa, Childrens Hosp Eastern Ontario, Ottawa, ON, Canada
[10] Med Univ Innsbruck, Dept Pediat 4, Div Pediat Neurol & Inborn Errors Metab, A-6020 Innsbruck, Austria
[11] Natl Pediat Hosp, Buenos Aires, DF, Argentina
[12] Univ Calif San Francisco, MS Ctr, San Francisco, CA 94143 USA
[13] Birmingham Childrens Hosp, Birmingham, W Midlands, England
关键词
ONSET MULTIPLE-SCLEROSIS; DEMYELINATING SYNDROMES; PSYCHOSOCIAL FEATURES; CHILDHOOD-ONSET; JUVENILE MS; CHILDREN; DISEASE; LESIONS; COHORT; ADULTS;
D O I
10.1212/WNL.0b013e318288694e
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Pediatric studies for new biological agents are mandated by recent legislation, necessitating careful thought to evaluation of emerging multiple sclerosis (MS) therapies in children with MS. Challenges include a small patient population, the lack of prior randomized clinical trials, and ethical concerns. The goal of this meeting was to assess areas of consensus regarding clinical trial design and outcome measures among academic experts involved in pediatric MS care and research. Methods: The Steering Committee of the International Pediatric MS Study Group identified key focus areas for discussion. A total of 69 meeting attendees were assembled, including 35 academic experts. Regulatory and pharmaceutical representatives also attended, and provided input, which informed academic expert consensus decisions. Results: The academic experts agreed that clinical trials were necessary in pediatric MS to obtain pharmacokinetic, safety and efficacy data, and regulatory approval allowing for greater medication access. The academic experts agreed that relapse was an appropriate primary outcome measure for phase III pediatric trials. An international standardized cognitive battery was identified. The pros and cons of various trial designs were discussed. Guidelines surrounding MRI studies, pharmacokinetics, pharmacodynamics, and registries were developed. The academic experts agreed that given the limited subject pool, a stepwise approach to the launch of clinical trials for the most promising medications is necessary in order to ensure study completion. Alternative approaches could result in unethical exposure of patients to trial conditions without gaining knowledge. Conclusion: Consensus points for conduct of clinical trials in the rare disease pediatric MS were identified amongst a panel of academic experts, informed by regulatory and industry stakeholders. Neurology (R) 2013; 80:1161-1168
引用
收藏
页码:1161 / 1168
页数:8
相关论文
共 50 条
  • [41] REPORT OF A MEETING OF THE INTERNATIONAL-BRACKEN-GROUP (IBG), YORK, OCTOBER 1987
    不详
    GEOGRAPHICAL JOURNAL, 1988, 154 : 309 - 310
  • [42] Recommendations for Methodology of Virtual Reality Clinical Trials in Health Care by an International Working Group: Iterative Study
    Birckhead, Brandon
    Khalil, Carine
    Liu, Xiaoyu
    Conoyitz, Samuel
    Rizzo, Albert
    Danovitch, Itai
    Bullock, Kim
    Spiegel, Brennan
    JMIR MENTAL HEALTH, 2019, 6 (01):
  • [43] REPORT OF THE 1991 INTERNATIONAL MEETING ON FUNDAMENTAL AND CLINICAL RESEARCH IN UROGENITAL CANCER
    KAKIZOE, T
    FRIEDELL, GH
    SOLOWAY, MS
    SUEMASU, K
    SHIMOSATO, Y
    MUKAI, K
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1992, 22 (01) : 60 - 65
  • [44] Correction to: Meeting abstracts from the 4th International Clinical Trials Methodology Conference (ICTMC) and the 38th Annual Meeting of the Society for Clinical Trials
    Steven Penegar
    Rebecca Lewis
    James Catto
    Joanne Cresswell
    Leyshon Griffiths
    Micki Hill
    John Kelly
    Allen Knight
    John McGrath
    Laura Wiley
    Hugh Mostafid
    Emma Hall
    Trials, 19
  • [45] Pruritus Assessment in Clinical Trials: Consensus Recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials
    Staender, Sonja
    Augustin, Matthias
    Reich, Adam
    Blome, Christine
    Ebata, Toshiya
    Ngoc Quan Phan
    Szepietowski, Jacek C.
    ACTA DERMATO-VENEREOLOGICA, 2013, 93 (05) : 509 - 514
  • [46] International symposium on emerging perspectives in clinical cancer research: meeting report
    K. S. Zänker
    E. Mihich
    Journal of Cancer Research and Clinical Oncology, 2004, 130 (8) : 491 - 495
  • [47] MENTORING IN PEDIATRIC ONCOLOGY CLINICAL TRIALS: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG) YOUNG INVESTIGATORS COMMITTEE
    Levy, Adam
    Gow, Kenneth
    Kim, Grace
    Maloney, Kelly
    PEDIATRIC BLOOD & CANCER, 2010, 54 (06) : 820 - 821
  • [48] Treatment of SLE: bridging the gap from clinical trials to the clinic - a meeting report
    Leonard H Calabrese
    Arthritis Research & Therapy, 15 (Suppl 2):
  • [49] Treatment of SLE: bridging the gap from clinical trials to the clinic a meeting report
    Calabrese, Leonard H.
    ARTHRITIS RESEARCH & THERAPY, 2013, 15
  • [50] REPORT OF SCIENTIFIC MEETING ON SOME DEVELOPMENTS IN METHODOLOGY OF CONTROLLED CLINICAL TRIALS IN CANCER
    ARMITAGE, P
    BLOCK, JB
    SARACCI, R
    INTERNATIONAL JOURNAL OF CANCER, 1974, 14 (05) : 576 - 579